Core Insights - Autonomix Medical, Inc. is advancing precision nerve-targeted treatments and has announced a follow-on market expansion study phase ("PoC 2") for its proof-of-concept trial [1] Company Overview - Autonomix is a medical device company focused on innovative technologies for diagnosing and treating diseases of the nervous system [3] - The company's first-in-class platform includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [3] - This technology aims to enable transvascular diagnosis and treatment of peripheral nervous system diseases throughout the body [3] Technology Development - The initial focus of the technology is on treating pain, particularly in pancreatic cancer, which causes severe pain and lacks reliable treatment options [4] - The technology serves as a platform for addressing various indications, including cardiology, hypertension, and chronic pain management across a wide disease spectrum [4] - The technology is currently investigational and has not yet received marketing clearance in the United States [4]

Core Insights - Autonomix Medical, Inc. has successfully completed the initial phase of its first-in-human proof-of-concept trial ("PoC 1") demonstrating clinically meaningful pain reduction in patients with pancreatic cancer pain [1][2] - The company plans to initiate a market expansion study ("PoC 2") targeting additional visceral cancers and earlier stage pancreatic cancer, expected to commence in Q2 2025 [1][2] Company Overview - Autonomix is a medical device company focused on innovative technologies for diagnosing and treating diseases involving the nervous system [3] - The company's platform technology includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [3] - The initial development of this technology is aimed at treating pain associated with pancreatic cancer, a condition currently lacking reliable treatment options [4] Future Prospects - The technology has the potential to address a wide range of indications beyond pancreatic cancer, including cardiology, hypertension, and chronic pain management [4] - The investigational technology has not yet received marketing clearance in the United States [4]